In an adult female patient with a long‑standing tracheostomy who remains symptomatic with cough and increased secretions after empiric levofloxacin, what are the appropriate next diagnostic and therapeutic steps?

Next Steps for Persistent Symptoms After Empiric Levofloxacin in a Tracheostomy Patient

Stop the levofloxacin and obtain a sputum culture immediately before starting any new antibiotics, as empiric therapy in tracheostomy patients is inappropriate in approximately one-third of cases and these patients frequently harbor multidrug-resistant organisms (MDROs) that require targeted therapy 1.

Immediate Diagnostic Actions

Obtain sputum culture before any antibiotic changes. In tracheostomy patients, approximately 50% harbor MDROs while 30% have only susceptible organisms 1. The most common pathogens include Enterobacterales, Pseudomonas aeruginosa, Acinetobacter species, Staphylococcus aureus, and Corynebacterium striatum 1.

Key Clinical Assessment Points

Determine if this represents:

• True lower respiratory tract infection requiring antibiotics
• Colonization (common in tracheostomy patients) not requiring treatment
• Non-infectious complications of the tracheostomy itself

Look specifically for:

• Fever, increased work of breathing, or hypoxemia (suggests true infection)
• Change in secretion color/volume alone without systemic signs (may be colonization)
• Positional symptoms or barking quality to cough (suggests mechanical/structural issues like granuloma or tracheomalacia) 2, 3

Why Levofloxacin May Have Failed

Levofloxacin is inadequate for many tracheostomy-associated infections. While respiratory fluoroquinolones like levofloxacin 750mg have activity against typical community-acquired pneumonia pathogens 4, tracheostomy patients have different microbiology:

• Pseudomonas coverage: Levofloxacin 750mg daily has some activity against P. aeruginosa 5, but resistance is common in healthcare-associated infections
• MRSA: Levofloxacin has no reliable MRSA coverage 4
• Gram-negative MDROs: Increasing resistance to fluoroquinolones in this population 1

Empiric Antibiotic Selection (If Clinically Indicated)

If the patient has systemic signs of infection (fever, hypoxemia, increased work of breathing) and you must start antibiotics before culture results:

Risk Stratify for MDROs

High-risk features for MDROs (if ≥2 present, assume MDRO) 1:

• Higher Charlson Comorbidity Index
• Prolonged hospitalization before tracheostomy
• Recent antibiotic exposure (especially within 3 months)
• Previous MDRO isolation

Antibiotic Regimen Based on Risk

For MDRO risk:

• Anti-pseudomonal beta-lactam: Piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, or meropenem 1g IV q8h 4, 5
• PLUS vancomycin 15mg/kg IV q12h (adjust to levels) for MRSA coverage 4

For lower MDRO risk (but this is uncommon in tracheostomy patients):

• Ceftriaxone 1-2g IV daily PLUS azithromycin 500mg daily 4

Critical Non-Infectious Considerations

Tracheostomy complications are extremely common and can mimic infection 6, 7:

Examine for:

• Suprastomal granulation tissue: Can cause cough, secretions, and positional symptoms 6, 2
• Tracheomalacia: Presents with barking cough and positional dyspnea 3
• Tube obstruction: Dried secretions causing partial obstruction 8, 7
• Tracheal stenosis: Progressive symptoms over weeks to months 6

If symptoms are positional or the cough has a barking quality, obtain bronchoscopy to evaluate for structural abnormalities 2, 3.

Management Algorithm

1. Obtain sputum culture immediately (before any antibiotic changes)
2. Assess for systemic infection signs: fever, hypoxemia, increased work of breathing
3. If systemically ill: Start anti-pseudomonal beta-lactam + vancomycin
4. If not systemically ill: Hold antibiotics and await culture results
5. Optimize secretion clearance: Humidification, saline instillation, suctioning 8, 7
6. Consider bronchoscopy if: positional symptoms, barking cough, or no improvement with appropriate antibiotics 2
7. De-escalate antibiotics once culture results available (within 48-72 hours)

Common Pitfalls

• Treating colonization as infection: Tracheostomy patients are universally colonized; treat only with systemic signs 1
• Inadequate MRSA/Pseudomonas coverage: Standard community-acquired pneumonia regimens are insufficient 4, 1
• Missing structural complications: Granulomas and tracheomalacia commonly cause persistent cough after tracheostomy 6, 2, 3
• Continuing empiric therapy without cultures: Leads to inappropriate treatment in one-third of cases 1